Gilead Sciences, Inc., 10% Owner at Xilio Therapeutics, Inc. (XLO), bought 485,250 shares at $0.76 ($369K) on 2024-04-02, disclosed to the SEC on 2024-04-03.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| Filing → |
| XLO | BUY | 2024-12-19 | $3.7M | — | Filing → |
| KYTX | BUY | 2024-02-13 | $20.0M | — | Filing → |
| RCUS | BUY | 2024-01-31 | $320.0M | — | Filing → |